These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

926 related items for PubMed ID: 19177319

  • 1. [Medical treatment of metastatic renal cell carcinoma after the approval and market entry of multitargeted tyrosine kinase inhibitors in Germany].
    Bolenz C, Trojan L, Honeck P, Schöppler G, Herrmann E, Alken P, Michel MS, Häcker A.
    Aktuelle Urol; 2009 Jan; 40(1):31-6. PubMed ID: 19177319
    [Abstract] [Full Text] [Related]

  • 2. Frequent dose interruptions are required for patients receiving oral kinase inhibitor therapy for advanced renal cell carcinoma.
    La Vine DB, Coleman TA, Davis CH, Carbonell CE, Davis WB.
    Am J Clin Oncol; 2010 Jun; 33(3):217-20. PubMed ID: 19745694
    [Abstract] [Full Text] [Related]

  • 3. Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib.
    Lee WJ, Lee JL, Chang SE, Lee MW, Kang YK, Choi JH, Moon KC, Koh JK.
    Br J Dermatol; 2009 Nov; 161(5):1045-51. PubMed ID: 19558553
    [Abstract] [Full Text] [Related]

  • 4. [Metastatic renal cell cancer in Germany in 2010. Impact of different target therapies].
    Siebels M, Hegele A, Varga Z, Oberneder R, Doehn C, Heinzer H, Deutsche Gesellschaft für Immun- und Targeted Therapie e.V. (DGFIT).
    Urologe A; 2011 Sep; 50(9):1110-7. PubMed ID: 21559917
    [Abstract] [Full Text] [Related]

  • 5. Impact of the incorporation of tyrosine kinase inhibitor agents on the treatment of patients with a diagnosis of advanced renal cell carcinoma: study based on experience at the Hospital Universitario Central de Asturias.
    Muriel C, Esteban E, Corral N, Fonseca PJ, Luque M, Berros JP, Fernández Y, Blay P, Fra J, Villanueva N, Sanmamed M, Pardo P, Izquierdo M, Vieitez JM, Estrada E, Lacave ÁJ.
    Clin Transl Oncol; 2010 Aug; 12(8):562-7. PubMed ID: 20709657
    [Abstract] [Full Text] [Related]

  • 6. [Impact of immunotherapy in metastatic kidney cancer in Germany after introduction of new target therapy--results of a telephone survey of the German Society of Immuno- and Targeted Therapy (DGFIT)].
    Siebels M, Staehler M, Hegele A, Varga Z, Oberneder R, Doehn C, Heinzer H, Deutsche Gesellschaft für Immun- und Targeted Therapie e.V. (DGFIT).
    Aktuelle Urol; 2010 Mar; 41(2):122-30. PubMed ID: 19937556
    [Abstract] [Full Text] [Related]

  • 7. [Interdisciplinary recommendations for the treatment of metastatic renal cell carcinoma].
    Miller K, Bergmann L, Jäger E, Jakse G, Wirth M, Keilholz U, interdisziplinäre Arbeitsgruppe Nierenzellkarzinom der Deutschen Krebsgesellschaft e.V. (DKG).
    Aktuelle Urol; 2009 Jan; 40(1):27-30. PubMed ID: 19177318
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Tyrosine kinase inhibitors in advanced renal cell carcinoma: the evolving treatment paradigm.
    Bukowski RM.
    Clin Genitourin Cancer; 2009 Jan; 7(1):9-10. PubMed ID: 19213661
    [No Abstract] [Full Text] [Related]

  • 10. [Role of VEGFR-TKIs in the treatment of renal cell carcinoma].
    Kondo T.
    Nihon Jinzo Gakkai Shi; 2012 Jan; 54(5):574-80. PubMed ID: 22991835
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Treatment with tyrosine kinase inhibitors for patients with differentiated thyroid cancer: the M. D. Anderson experience.
    Cabanillas ME, Waguespack SG, Bronstein Y, Williams MD, Feng L, Hernandez M, Lopez A, Sherman SI, Busaidy NL.
    J Clin Endocrinol Metab; 2010 Jun; 95(6):2588-95. PubMed ID: 20392874
    [Abstract] [Full Text] [Related]

  • 20. Use of tyrosine kinase inhibitors in patients with metastatic kidney cancer receiving haemodialysis: a retrospective Italian survey.
    Masini C, Sabbatini R, Porta C, Procopio G, Di Lorenzo G, Onofri A, Buti S, Iacovelli R, Invernizzi R, Moscetti L, Aste MG, Pagano M, Grosso F, Lucia Manenti A, Ortega C, Cosmai L, Del Giovane C, Conte PF.
    BJU Int; 2012 Sep; 110(5):692-8. PubMed ID: 22364110
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 47.